Exhibit 99.1

Food and Drug Administration

New Jersey District Office

Central Region

Waterview Corporate Center

10 Waterview Blvd. 3rd Floor

Parsippany, New Jersey 07054

Telephone: (973) 331-4900

FAX: (973) 331-4969

September 24, 2013

Integra LifeSciences Corporation

Attention: Peter J. Arduini, President & CEO

311 Enterprise Drive

Plainsboro, New Jersey 08536

Dear Mr. Arduini:

The Food and Drug Administration has completed an evaluation of your corrective actions in response to our Warning Letter 12-NWJ-04, dated December 21, 2011. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,

/S/

Capt. Joseph F. McGinnis

Director Compliance Branch

New Jersey District